Search | Invivogen

VET-SAP® saponin adjuvant

Saponin vaccine adjuvant - CAS #8047-15-2

Default product image

CL429 VacciGrade™ - TLR2 & NOD2-based Adjuvant

Pam2C-conjugated murabutide

Dose-dependent NF-κB response to CL429 in HEK-Blue™ hTLR2 and HEK-Blue™ hNOD2 cells

CL429 chemical structure

Pam3CSK4 VacciGrade™ - TLR2/TLR1-based Adjuvant

Synthetic triacylated lipopeptide | Th1 response

Evaluation of NF-κB activation with Pam3CSK4

Specificity of Pam3CSK4 activation

ODN 1585 VacciGrade™ - TLR9-based Adjuvant

CpG ODN, Class A (Mouse) | Th1 response

Dose-dependent NF-κB response of ODN 1585 in HEK-Blue™ mTLR9 cells

NF-κB and IRF responses of ODN 1585 in THP1-Dual™ hTLR9 cells

TDB - Mincle Agonist

Synthetic analog of the cord factor

TDB dose-dependent activation of Mincle

NF-κB response to various Mincle agonists in HEK-Blue™ hMincle cells

CL413 VacciGrade™ - TLR2 & TLR7-based Adjuvant

Chimeric molecule | Th1/Th2 response

Tumor growth after CL413 or CL401 treatment

Survival curves for untreated as well as CL413- or CL401-treated mice

CL413 chemical structure

CL401 VacciGrade™ - TLR2 & TLR7-based Adjuvant

Pam2C-conjugated 8-hydroxyadenine| Th1/Th2 response

Tumor growth after CL413 or CL401 treatment

Survival curves for untreated as well as CL413- or CL401-treated mice

Anti-OVA mIgG levels at 15, 30 and 45 days after the initial immunization in different groups.

Anti-OVA total IgG, IgG1, and IgG2a levels 45 days after the initial immunization in different groups.

Quil-A® adjuvant

Saponin vaccine adjuvant

Default product image

HKCA - Dectin-1 Agonist

Heat-killed Candida albicans

HKCA dose-dependent activation of Dectin-1

NF-κB response to various Dectin-1 agonists in HEK-Blue™ hDectin-1a cells

Curdlan - Dectin-1 Agonist

Beta-1,3-glucan from Alcaligenes faecalis

Curdlan dose-dependent activation of Dectin-1

NF-κB response to various Dectin-1 agonists in HEK-Blue™ hDectin-1a cells

Partial structure of Curdlan

Depleted Zymosan - Dectin-1 Agonist

Hot alkali–treated zymosan — Selective Dectin-1 agonist, depleted of TLR2 activity

Zymosan Depleted dose-dependent activation of Dectin-1

NF-κB response to various Dectin-1 agonists in HEK-Blue™ hDectin-1a cells

Furfurman - Dectin-2 Agonist

Malassezia furfur cell wall preparation

Furfurman dose-dependent activation of Dectin-2

LPS-EB VacciGrade™ - TLR4-based Adjuvant

Lipopolysaccharide from E. coli 0111:B4 | Th1 response

LPS-EB Vaccigrade™-dependent activation of TLR4

TDB VacciGrade™ - Mincle-based Adjuvant

Synthetic analog of the cord factor | Th1 response

TDB dose-dependent activation of Mincle

ODN 2395 VacciGrade™ - TLR9-based Adjuvant

CpG ODN, Class C (Human/mouse) | Th1 response

NF-κB response in HEK-Blue™-derived cells upon ODN 2395 stimulation

NF-κB and IRF response upon ODN 2395 stimulation

CFA

Complete Freund’s Adjuvant | Th1 response

Anti-Ova mIgG levels at 15 and 30 days after the initial immunization with CFA

Laminarin - Dectin-1 Ligand

Soluble beta-glucan from Laminaria digitata - Dectin-1 Antagonist or Agonist

Laminarin dose-dependent activation of Dectin-1a

NF-κB response to various Dectin-1 agonists in HEK-Blue™ hDectin-1a cells

Partial structure of Laminarin

OVA peptides

Two OVA peptide standards for ELISPOT

Default product image

OVA protein

OVA (ovalbumin) for in vitro use

Default product image

EndoFit™ OVA protein

OVA (ovalbumin) for in vivo use

Anti-Ova mIgG levels at 15, 30 and 45 days after the initial immunization with IFA